Longitudinal head-to-head comparison of ¹¹C-PiB and ¹⁸F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's disease.

ABSTRACT:

Purpose

Pittsburgh Compound-B (¹¹C-PiB) and ¹⁸F-florbetapir are amyloid-β (Aβ) positron emission tomography (PET) radiotracers that have been used as endpoints in Alzheimer's disease (AD) clinical trials to evaluate the efficacy of anti-Aβ monoclonal antibodies. However, comparing drug effects between and within trials may become complicated if different Aβ radiotracers were used. To study the consequences of using different Aβ radiotracers to measure Aβ clearance, we performed a head-to-head comparison of ¹¹C-PiB and ¹⁸F-florbetapir in a Phase 2/3 clinical trial of anti-Aβ monoclonal antibodies.

Methods

Sixty-six mutation-positive participants enrolled in the gantenerumab and placebo arms of the first Dominantly Inherited Alzheime

SUBMITTER: Chen CD 

PROVIDER: S-EPMC10330155 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature